Diagnosis, impact, and management of focal hyperhidrosis: treatment review including botulinum toxin therapy.
Idiopathic localized hyperhidrosis, called for hyperhidrosis, affects almost 3% of the US population. The most frequent anatomic sites of involvement include the axillae, palms, soles, and face. For those affected, this condition can be extremely socially debilitating and interfere with work activities. Until recently, frequently ineffective topical regimens or problematic surgical procedures have been the treatments of choice. Since 1996, intracutaneous injections of botulinum toxin have been used as a minimally invasive treatment for this condition with numerous studies documenting safety, efficacy, and extremely high levels of patient satisfaction. Botulinum toxin type A (Botox) was approved by the US Food and Drug Administration in 2004 for the treatment of axillary hyperhidrosis.
Cohen
Joel L
JL
AboutSkin Dermatology and DermSurgery, Englewood, CO 80113, USA. denverskindoc@yahoo.com
Cohen
Goldie
G
Solish
Nowell
N
Murray
Christian A
CA
D000447:Aldehydes / Q000627:therapeutic use; D000077410:Aluminum Chloride; D017607:Aluminum Compounds / Q000627:therapeutic use; D000777:Anesthetics / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002712:Chlorides / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D000529:Complementary Therapies; D006801:Humans; D006945:Hyperhidrosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000628:therapy; D007478:Iontophoresis; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D013562:Sympathectomy
D000447:Aldehydes; D017607:Aluminum Compounds; D000777:Anesthetics; D002712:Chlorides; D018680:Cholinergic Antagonists; D009465:Neuromuscular Agents; D000077410:Aluminum Chloride; D019274:Botulinum Toxins, Type A